First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology - United Kingdom
doi 10.1002/hon.105_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab-Vedotin and Bendamustine Is a Feasible and Effective Drug Combination as First-Line Treatment of Hodgkin Lymphoma in the Elderly (Halo Trial)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Haematologica
Hematology
2015English

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy